Michael J. Mancino

CAST Program Director

UAMS

Last publication 2026 Last refreshed 2026-05-16

faculty

PSY Psychiatry, College of Medicine

16 h-index 62 pubs 882 cited

Research Areas

Links

ORCID Lab Website UAMS TRI Profile

OverviewAI-generated summary

Dr. Michael J. Mancino, a Professor in the Department of Psychiatry at the University of Arkansas for Medical Sciences (UAMS), directs the Center for Addiction Services and Treatment within the Psychiatric Research Institute. His work focuses on the treatment of substance use disorders, particularly opioid and methamphetamine use. Dr. Mancino has investigated various pharmacological and behavioral interventions aimed at improving treatment outcomes and patient retention.

His research has explored the utility of different medications, including buprenorphine and gabapentin, in managing withdrawal symptoms and supporting long-term recovery. He has also examined factors influencing treatment retention, such as anxiety severity, and has studied the effectiveness of smartphone-based interventions for individuals with opioid use disorder. Dr. Mancino's publications include studies on the development of analytical methods for quantifying medications in biological samples and investigations into geographic and demographic differences in access to treatment services.

With an h-index of 16 and 62 total publications, Dr. Mancino has contributed significantly to the field. He actively collaborates with researchers at UAMS, including Alison Oliveto, with whom he shares 13 publications. His work is supported by grants and his research is further disseminated through an active lab website.

Research Overview

Dr. Michael J. Mancino is a Professor in the UAMS Department of Psychiatry and the program director of the Center for Addiction Services and Treatment in the Psychiatric Research Institute.

Metrics

h-index: 16
Publications: 62
Citations: 882

Selected Publications

Randomized, placebo-controlled trial of gabapentin during outpatient buprenorphine-assisted taper and transition to injectable naltrexone (2025)

DOI OpenAlex
Exploratory study of heart rate variability among participants with opioid use disorder inducted on gabapentin versus placebo during outpatient buprenorphine-assisted transition to injection naltrexone. (2025)

DOI OpenAlex
Study Protocol for Implementation of Pharmacist-Led Interventions to Increase Access to Medications for Opioid Use Disorder for Incarcerated Individuals (PLI-MOUD Study) (2025)

DOI OpenAlex
A randomized clinical trial of disulfiram at higher doses for the treatment of cocaine use disorder among methadone-stabilized patients (2025)

DOI OpenAlex
Gabapentin and D-cycloserine alone and in combination with naloxone in methadone-maintained humans responding under a naloxone novel-response discrimination procedure (2025)

DOI OpenAlex
Worsening trends in the frequency of methamphetamine and other stimulant use between treatment admission and discharge (2024)

1 citation DOI OpenAlex
THE IMPACT OF FENTANYL ON TREATMENT OUTCOMES DURING AN OUTPATIENT BUPRENORPHINE TAPER WITH ADJUNCT GABAPENTIN (2024)

DOI OpenAlex
Geographic and Racial/Ethnic Differences in Access to Methamphetamine Detoxification Services, United States, 2021 (2024)

4 citations DOI OpenAlex
484 A Preliminary Study on the Pharmacodynamics of Oral Cannabis Ingestion in Older Adults (2024)

DOI OpenAlex
289 Heart Rate Variability in Opioid Use Disordered Participants Undergoing Buprenorphine-Assisted Detoxification (2023)

DOI OpenAlex
Smartphone intervention to optimize medication-assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial (2023)

3 citations DOI OpenAlex
Smartphone intervention to optimize medication assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial (2023)

DOI OpenAlex
Impact of state and trait anxiety severity on retention and phase advancement in an outpatient buprenorphine treatment program (2022)

1 citation DOI OpenAlex
Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial (2021)

11 citations DOI OpenAlex
Development and validation of a rapid liquid chromatography/tandem mass spectrometry method to quantitate gabapentin and buprenorphine in human serum (2021)

6 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

Efficacy of Carvedilol in Recently-Abstinent Psychostimulant Dependent Patients NIH/Nat. Inst. on Drug Abuse - Pass Through: Baylor College of Medicine Co-Investigator
CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) NIH/Nat. Inst. on Drug Abuse - Pass Through: New York University Principal Investigator
Clinical Trials Network: The Big South/West Node NIH/Nat. Inst. on Drug Abuse - Pass Through: University of Texas Southwestern Medical Center Principal Investigator
ADAP Substance Abuse Treatment Clinic FY24 Substance Abuse & Mental Health Services Administration - Pass Through: Arkansas Department of Human Services Principal Investigator
Expanding Infant Mental Health Services in AR Substance Abuse & Mental Health Services Administration - Pass Through: AR Dept of Human Services/Division of Aging and Adult Services Principal Investigator
University of Arkansas for Medical Sciences - Substance Abuse Treatment Clinic Arkansas Department of Health & Human Services Principal Investigator
Improving Treatment Outcomes for Prescription Opioid Dependence - Continuation - Continuation - Continuation - Continuation NIH/Nat. Inst. on Drug Abuse Co-Principal Investigator
Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence NIH Principal Investigator